Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Pa (Q53132420)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 December 2013

Language	Label	Description	Also known as
English	Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Pa	scientific article published on 10 December 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Pa (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

10

object named as

Gerard Socie

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

2

object named as

Myriam Labopin

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

15

object named as

Johan Maertens

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

12

object named as

Harry C Schouten

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

3

object named as

Didier Blaise

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

author name string

Moshe Yeshurun

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Jan J Cornelissen

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Henrik Sengeloev

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Lars Vindelov

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Juergen Kuball

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Patrice Chevallier

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Charles Craddock

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Karin Bilger

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Nathalie Fegueux

13

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Hakan Goker

14

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Donald Bunjes

16

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Renate Arnold

17

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Arnon Nagler

18

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Mohamad Mohty

19

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

language of work or name

0 references

publication date

10 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

120

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

855-863

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis fro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

21 January 2018

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

7 January 2021

based on heuristic

inferred from DOI database lookup

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28498

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28498

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24338939

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53132420&oldid=1776802683"